Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

Gut

Volumn 62, Issue 11, 2013, Pages 1634-1641

  Reiberger, Thomas ^a   Ulbrich, Gregor ^b   Ferlitsch, Arnulf ^a   Payer, Berit Anna ^a   Schwabl, Philipp ^a   Pinter, Matthias ^a   Heinisch, Birgit B ^a   Trauner, Michael ^a   Kramer, Ludwig ^b   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PROPRANOLOL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CONTROL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPIC BAND LIGATION; ESOPHAGOSCOPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEADACHE; HEMODYNAMICS; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; LIGATION; LIVER CIRRHOSIS; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; PORTAL HYPERTENSION; PRESSURE GRADIENT; PRIORITY JOURNAL; TREATMENT RESPONSE; VERTIGO;

BLEEDING; CIRRHOSIS; PORTAL HYPERTENSION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HUMANS; KAPLAN-MEIER ESTIMATE; LIGATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPANOLAMINES; PROPRANOLOL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84885620219     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-304038     Document Type: Article

References (27)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhotic. I. Portal hypertension. J Hepatol 2000;32:141-56.
2. Ferlitsch M, Reiberger T, Hoke M, et al. Von Willebrand factor as new non-invasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhotic. Hepatology 2012;124:395-402.
3. Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24. (Pubitemid 15065948)
4. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7. (Pubitemid 20381877)
5. Cerqueira RM, Andrade L, Correia MR, et al. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol 2012;24:551-7.
6. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhotic. Hepatology 2003;37:902-8. (Pubitemid 36397403)
7. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhotic. Hepatology 2000;32: 930-4.
8. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhotic: a systematic review. Gastroenterology 2006;131:1611-24. (Pubitemid 44708947)
9. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-8.
10. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002;123:728-34.
11. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6. (Pubitemid 36667304)
12. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic. Hepatology 2004;40:65-72. (Pubitemid 38868924)
13. Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-93. (Pubitemid 29157630)
14. Bosch J. Carvedilol for portal hypertension in patients with cirrhotic. Hepatology 2010;51:2214-18.
15. Hemstreet BA. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy 2004;24:94-104. (Pubitemid 38056255)
16. Tsochatzis EA, Triantos CK, Burroughs AK. Gastrointestinal bleeding: carvedilol-the best beta-blocker for primary prophylaxis? Nat Rev Gastroenterol Hepatol 2009;6:692-4.
17. Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhotic. J Hepatol 1996;25:909-15. (Pubitemid 27008124)
18. Banares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhotic. Hepatology 1999;30:79-83. (Pubitemid 29300572)
19. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhotic. Hepatology 2002;36:1367-73. (Pubitemid 35403527)
20. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825-33.
21. Peck-Radosavljevic M, Trauner M, Schreiber F. Austrian consensus on the definition and treatment of portal hypertension and its complications. Endoscopy 2005;37:667-73. (Pubitemid 40936503)
22. Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhotic. J Gastroenterol 2011;47:561-8.
23. Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82.
24. Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011;9:602-8e1.
25. Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-a large single center experience. Wien Klin Wochenschr 2012;56:1439-47.
26. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001;33:802-7. (Pubitemid 32246627)
27. Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhotic and refractory ascites. Hepatology 2010;52:1017-22.